MCID: OST002
MIFTS: 75

Osteoporosis

Categories: Genetic diseases, Rare diseases, Fetal diseases, Bone diseases

Aliases & Classifications for Osteoporosis

MalaCards integrated aliases for Osteoporosis:

Name: Osteoporosis 53 37 12 72 71 36 51 40 41 14 69 59
Osteoporosis, Postmenopausal 53 41 69
Postmenopausal Osteoporosis 71 28
Osteoporosis, Involutional 53 13
Bone Mineral Density Quantitative Trait Locus; Bmnd 53
Bone Mineral Density Variation Qtl, Osteoporosis 53
Bone Mineral Density Quantitative Trait Locus 53
Osteoporosis, Postmenopausal, Susceptibility 53
Osteoporosis, Susceptibility to 53
Osteoporosis Postmenopausal 51
Involutional Osteoporosis 71
Osteoporosis, Senile 69
Senile Osteoporosis 71
Osteop 71
Bmnd 53

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
osteoporosis:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 166710
Disease Ontology 12 DOID:11476
ICD10 32 M81.0 M80.0
ICD9CM 34 733.0 733.00
NCIt 46 C3298
KEGG 36 H01593
SNOMED-CT via HPO 65 263681008

Summaries for Osteoporosis

MedlinePlus : 40 Osteoporosis is a disease that thins and weakens the bones. Your bones become fragile and break easily, especially the bones in the hip, spine, and wrist. In the United States, millions of people either already have osteoporosis or are at high risk due to low bone mass. Anyone can develop osteoporosis, but it is more common in older women. Risk factors include Getting older Being small and thin Having a family history of osteoporosis Taking certain medicines Being a white or Asian woman Having low bone density Osteoporosis is a silent disease. You might not know you have it until you break a bone. A bone mineral density test is the best way to check your bone health. To keep bones strong, eat a diet rich in calcium and vitamin D, exercise, and do not smoke. If needed, medicines can also help. It is also important to try to avoid falling down. Falls are the number one cause of fractures in older adults. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Osteoporosis, also known as osteoporosis, postmenopausal, is related to osteoporosis, juvenile and glucocorticoid-induced osteoporosis, and has symptoms including equilibration disorder, tremor and sciatica. An important gene associated with Osteoporosis is COL1A2 (Collagen Type I Alpha 2 Chain), and among its related pathways/superpathways are Osteoclast differentiation and Mineral absorption. The drugs Alendronate and Etidronic acid have been mentioned in the context of this disorder. Affiliated tissues include Bone and Bone, and related phenotypes are limbs/digits/tail and craniofacial

UniProtKB/Swiss-Prot : 71 Osteoporosis: A systemic skeletal disorder characterized by decreased bone mass and deterioration of bone microarchitecture without alteration in the composition of bone. The result is fragile bones and an increased risk of fractures, even after minimal trauma. Osteoporosis is a chronic condition of multifactorial etiology and is usually clinically silent until a fracture occurs.

Disease Ontology : 12 A bone resorption disease characterized by decreased density of normally mineralized bone which results_in the thinning of bone tissue and decreased mechanical strength.

PubMed Health : 59
About osteoporosis: Having weak bones that easily break is a sign of osteoporosis. It is normal for your bones to become less dense as you grow older, but osteoporosis speeds up this process. This condition can particularly lead to problems in older age because broken bones do not heal as easily in older people as they do in young people, and the consequences are more serious. In general, osteoporosis is more common in women, and they often develop it at a younger age.Getting older does not mean that you will automatically develop osteoporosis, but the risk does increase with age. People over the age of 70 are more likely to have low bone density. Plus, the risk of falling increases in old age, which then also makes fractures more likely.But there are several things you can do to protect and strengthen your bones – even if you are already older.

Wikipedia : 72 Osteoporosis is a disease where increased bone weakness increases the risk of a broken bone. It is the... more...

Description from OMIM: 166710

Related Diseases for Osteoporosis

Diseases in the Osteoporosis family:

Osteoporosis, Juvenile Juvenile Primary Osteoporosis

Diseases related to Osteoporosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 452)
# Related Disease Score Top Affiliating Genes
1 osteoporosis, juvenile 35.4 BGLAP CALCA COL1A1 LRP5 WNT1
2 glucocorticoid-induced osteoporosis 34.9 BGLAP CALCA TNFRSF11B TNFSF11
3 bone mineral density quantitative trait locus 15 33.9 CALCR PDLIM4
4 rickets 33.0 BGLAP SLC34A1 VDR
5 osteopetrosis 32.8 LRP5 TNFRSF11A TNFSF11
6 osteogenesis imperfecta, type viii 32.3 COL1A1 COL1A2
7 osteoporotic fracture 31.6 COL1A1 ESR1 TNFRSF11B
8 osteomalacia 31.5 BGLAP CALCA VDR
9 osteonecrosis 31.5 BGLAP TNFRSF11B TNFSF11
10 cohen-gibson syndrome 31.4 BGLAP TNFRSF11A TNFRSF11B TNFSF11
11 hyperparathyroidism 31.4 BGLAP CALCA TNFRSF11B VDR
12 periodontitis 31.4 BGLAP TNFRSF11B TNFSF11
13 brittle bone disorder 31.2 BGLAP COL1A1 COL1A2
14 paget's disease of bone 31.2 BGLAP CALCA TNFRSF11A TNFRSF11B TNFSF11
15 spondyloarthropathy 1 31.1 BGLAP TNFRSF11B TNFSF11
16 secondary hyperparathyroidism of renal origin 31.1 BGLAP CALCA TNFRSF11B VDR
17 otosclerosis 31.1 COL1A1 COL1A2 TNFRSF11B VDR
18 primary hyperparathyroidism 31.1 BGLAP CALCA VDR
19 hyperostosis 31.0 COL1A1 LRP5 TNFRSF11B
20 periodontal disease 31.0 TNFRSF11A TNFRSF11B TNFSF11
21 endosteal hyperostosis, autosomal dominant 30.9 LRP5 TNFRSF11B TNFSF11
22 hemophilic arthropathy 30.8 TNFRSF11A TNFRSF11B TNFSF11
23 renal osteodystrophy 30.7 BGLAP CALCA TNFRSF11B VDR
24 kummell's disease 30.3 TNFRSF11B TNFSF11
25 chronic kidney failure 30.1 BGLAP CALCA VDR
26 osteoporosis-pseudoglioma syndrome 12.5
27 juvenile primary osteoporosis 12.3
28 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.2
29 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.2
30 osteoporosis and oculocutaneous hypopigmentation syndrome 12.1
31 growth failure, microcephaly, mental retardation, cataracts, large joint contractures, osteoporosis, cortical dysplasia, and cerebellar atrophy 11.9
32 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 11.9
33 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 11.9
34 cutis laxa osteoporosis 11.8
35 dominant hypophosphatemia with nephrolithiasis or osteoporosis 11.8
36 osteoporosis-macrocephaly-blindness-joint hyperlaxity syndrome 11.8
37 lrp5-related primary osteoporosis 11.8
38 hajdu-cheney syndrome 11.8
39 bone mineral density quantitative trait locus 8 11.7
40 bone mineral density quantitative trait locus 18 11.7
41 acroosteolysis dominant type 11.6
42 bone mineral density quantitative trait locus 16 11.5
43 werner syndrome 11.2
44 lysinuric protein intolerance 11.2
45 mental retardation, x-linked, syndromic, snyder-robinson type 11.1
46 syndromic x-linked intellectual disability snyder type 11.1
47 acth-secreting pituitary adenoma 11.1
48 bone resorption disease 11.1 BGLAP CALCA COL1A1 ESR1 LRP5 TNFRSF11A
49 bone fracture 11.1
50 bone remodeling disease 11.1 BGLAP CALCA ESR1 LRP5 TNFRSF11A TNFRSF11B

Comorbidity relations with Osteoporosis via Phenotypic Disease Network (PDN): (show top 50) (show all 87)


Active Peptic Ulcer Disease Acute Cor Pulmonale
Acute Cystitis Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Asthma
Benign Essential Hypertension Bronchiectasis
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Chylomicron Retention Disease
Conjunctivitis Conn's Syndrome
Cystitis Decubitus Ulcer
Deficiency Anemia Dermatomycosis
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Femoral Vein Thrombophlebitis
Gastroesophageal Reflux Generalized Anxiety Disorder
Generalized Atherosclerosis Heart Disease
Hyperparathyroidism Hypertension, Essential
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome Hypothyroidism
Idiopathic Interstitial Pneumonia Inflammatory Bowel Disease 1
Intervertebral Disc Disease Intestinal Obstruction
Iron Deficiency Anemia Irritable Bowel Syndrome
Macular Degeneration, Age-Related, 1 Major Depressive Disorder
Marasmus Monoclonal Paraproteinemia
Neurogenic Bladder Nutritional Deficiency Disease
Opioid Addiction Oral Candidiasis

Graphical network of the top 20 diseases related to Osteoporosis:



Diseases related to Osteoporosis

Symptoms & Phenotypes for Osteoporosis

Symptoms via clinical synopsis from OMIM:

53
Skel:
postmenopausal osteoporosis


Clinical features from OMIM:

166710

Human phenotypes related to Osteoporosis:

31
# Description HPO Frequency HPO Source Accession
1 osteoporosis 31 HP:0000939

UMLS symptoms related to Osteoporosis:


equilibration disorder, tremor, sciatica, pelvic pain, muscle cramp, back pain, angina pectoris

MGI Mouse Phenotypes related to Osteoporosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 limbs/digits/tail MP:0005371 9.81 TNFRSF11B TNFSF11 VDR CALCR COL1A1 COL1A2
2 craniofacial MP:0005382 9.8 TNFRSF11B TNFSF11 VDR WNT1 COL1A1 LRP5
3 muscle MP:0005369 9.5 TNFSF11 VDR WNT1 COL1A1 COL1A2 ESR1
4 skeleton MP:0005390 9.36 TNFRSF11B TNFSF11 VDR CALCR WNT1 COL1A1

Drugs & Therapeutics for Osteoporosis

PubMedHealth treatment related to Osteoporosis: 59

Even if someone already has osteoporosis, it is important for them to do regular exercise and get enough calcium and vitamin D. In Germany, statutory health insurances cover the cost of calcium or vitamin D supplements if a doctor has prescribed them.Osteoporosis can be treated with several drugs designed to slow bone loss and increase the production of new bone tissue. These include bisphosphonates and some hormonal or hormone-like medications. These kinds of drugs can have different types of side effects, though, and may not be suitable for everyone. They are only considered if someone has already broken a bone, or if their risk of bone fractures is high – for example, if their bone density is very low or if they have a combination of different risk factors, like low body weight, old age and a higher risk of falling.Hormone products, like those used to treat menopause symptoms, can also lower the risk of osteoporosis-related bone fractures when taken over the long term. But long-term hormone therapy during or after menopause increases the risk of cardiovascular diseases and breast cancer. For this reason it is only rarely recommended as treatment for osteoporosis. The pros and cons of this treatment should be carefully weighed.

Drugs for Osteoporosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 626)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 2,Phase 3,Phase 1 121268-17-5, 66376-36-1 2088
2
Etidronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 2809-21-4, 7414-83-7 3305
3
Linagliptin Approved Phase 4 668270-12-0 10096344
4
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
5
Teriparatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52232-67-4 16133850
6
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
7
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 471-34-1
8
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 615258-40-7
9
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
10
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1 71-58-9
11
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2 57-83-0 5994
12
Zoledronic acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
13
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
15
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
16
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
17
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
18
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
19
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2 112809-51-5 3902
20
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
21
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
22
Methyltestosterone Approved Phase 4,Phase 2,Phase 3 58-18-4 6010
23
Testosterone Approved, Investigational Phase 4,Phase 2,Phase 3 58-22-0 6013
24
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2 174722-31-7 10201696
25
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
26
Demeclocycline Approved Phase 4,Phase 2 127-33-3 5311063
27
Tetracycline Approved, Vet_approved Phase 4,Phase 2 60-54-8 5353990
28
Bazedoxifene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198481-32-2
29
Tibolone Approved, Investigational Phase 4,Phase 3,Phase 2 5630-53-5
30
Esomeprazole Approved, Investigational Phase 4,Phase 1 161796-78-7, 119141-88-7 9579578 4594
31
Acetaminophen Approved Phase 4,Phase 3,Phase 1 103-90-2 1983
32
Fluvastatin Approved Phase 4 93957-54-1 1548972
33
Pamidronate Approved Phase 4,Phase 2,Phase 1 40391-99-9 4674
34
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Phase 3
35
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
36
Gliclazide Approved Phase 4 21187-98-4 3475
37
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
38
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
39
Budesonide Approved Phase 4 51333-22-3 5281004 63006
40
Montelukast Approved Phase 4 158966-92-8 5281040
41
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
42
Topiramate Approved Phase 4 97240-79-4 5284627
43
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
44
Salmon Calcitonin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 47931-85-1 16129616
45
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
46
Lopinavir Approved Phase 4 192725-17-0 92727
47
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
48
Azathioprine Approved Phase 4 446-86-6 2265
49
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
50
Ethanol Approved Phase 4 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 1748)

# Name Status NCT ID Phase Drugs
1 Osteoporosis and Dental Implant Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
2 Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis Unknown status NCT01675297 Phase 4 Risedronate/Cholecalciferol combination;Risedronate
3 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
4 Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
5 Determination of Vitamin D Dose to Maintain Sufficiency Amongst Indian and Malay Women in the Tropics Unknown status NCT02389179 Phase 4 Vitamin D3
6 To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women Unknown status NCT01904110 Phase 4 Risedronate/Cholecalciferol combination(montly);Risedronate/Cholecalciferol combination(weekly)
7 The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
8 Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
9 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
10 Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women Unknown status NCT01926158 Phase 4 Denosumb;Placebo (for denosumab)
11 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
12 The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion Unknown status NCT01310465 Phase 4 zoledronic acid;sodium chloride
13 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
14 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
15 Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen Unknown status NCT01560572 Phase 4 tacrolimus OD, mycophenolic acid, prednisolone
16 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
17 Alendronate for Vascular Calcification in Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
18 A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids Unknown status NCT00273559 Phase 4 prednisone
19 Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors Unknown status NCT00111241 Phase 4 aromatase inhibitors (letrozole, anastrozole)
20 Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis Completed NCT01544894 Phase 4 Raloxifene;Strontium ranelate
21 Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window? Completed NCT01166958 Phase 4 Teriparatide;Raloxifene
22 Teriparatide Treatment in Patients With Inherited Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
23 Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM) Completed NCT00479037 Phase 4 Full Length Parathyroid Hormone, PTH(1-84);Strontium Ranelate
24 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
25 Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate Completed NCT00327990 Phase 4 Ibandronate;Alendronate
26 ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis. Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
27 Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use Completed NCT00221299 Phase 4 Risedronate;Parathyroid Hormone
28 A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia Completed NCT02604836 Phase 4 Ibandronate
29 Danish Osteoporosis Prevention Study Completed NCT00252408 Phase 4 Hormone replacement therapy
30 A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP) Completed NCT00545363 Phase 4 Ibandronate
31 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis Completed NCT01753856 Phase 4 Teriparatide;Denosumab;Demeclocycline;Tetracycline;Calcium Supplement;Vitamin D
32 STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES) Completed NCT00583518 Phase 4 Parathyroid hormone (PTH)
33 A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis Completed NCT02598440 Phase 4 Alendronate;Ibandronate
34 A Study of Teriparatide in Japanese Osteoporosis Patients Completed NCT01430104 Phase 4 Teriparatide;Aspara-CA 600 mg;Alfarol 1.0 µg
35 A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis Completed NCT02598934 Phase 4 Ibandronate
36 A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women Completed NCT00860964 Phase 4 Placebo;estradiol valerate
37 PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia Completed NCT02598453 Phase 4 Ibandronate
38 HRT Versus Etidronate for Osteoporosis and Fractures in Asthmatics Receiving Glucocorticoids. Completed NCT00376662 Phase 4 Hormone Replacement Therapy and Etidronate
39 High Dosage Vitamin D and Osteoporosis Completed NCT00491920 Phase 4 cholecalciferol (Vitamin D3);placebo
40 Prevention of Osteoporosis in Breast Cancer Survivors Completed NCT00567606 Phase 4
41 The Prevalence of Osteoporosis in Hemodialysis Patients Completed NCT00308828 Phase 4
42 Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)
43 Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis Completed NCT00259298 Phase 4 teriparatide
44 A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. Completed NCT00545051 Phase 4 Placebo;ibandronate
45 BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis Completed NCT00545909 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
46 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis Completed NCT00191425 Phase 4 Teriparatide;Raloxifene
47 SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis. Completed NCT00545480 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
48 A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment Completed NCT00551174 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
49 A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo Completed NCT00148915 Phase 4 ibandronate;Placebo
50 A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate) Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]

Search NIH Clinical Center for Osteoporosis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteoporosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteoporosis:
PREOB

Cochrane evidence based reviews: osteoporosis, postmenopausal

Genetic Tests for Osteoporosis

Genetic tests related to Osteoporosis:

# Genetic test Affiliating Genes
1 Postmenopausal Osteoporosis 28 CALCR COL1A1 COL1A2 LRP5 PDLIM4 VDR

Anatomical Context for Osteoporosis

MalaCards organs/tissues related to Osteoporosis:

38
Bone, Breast, Prostate, Spinal Cord, Testes, Kidney, Bone Marrow
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Osteoporosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Mononucleated Osteoclasts Affected by disease
2 Bone Bone Marrow Multinucleated Osteoclasts Affected by disease
3 Blood Hematopoietic Bone Marrow Osteoclast Precursor Cells Affected by disease

Publications for Osteoporosis

Articles related to Osteoporosis:

(show top 50) (show all 2599)
# Title Authors Year
1
Relationship between osteoporosis and expression of Bcl-2 and CXCL12. ( 29434715 )
2018
2
Low Grip Strength is a Strong Risk Factor of Osteoporosis in Postmenopausal Women. ( 29430846 )
2018
3
Denosumab: A Review in Postmenopausal Osteoporosis. ( 29435849 )
2018
4
Screening for Geriatric Syndromes: Falls, Urinary/Fecal Incontinence, and Osteoporosis. ( 29129217 )
2018
5
MiRNA-133a is involved in the regulation of postmenopausal osteoporosis through promoting osteoclast differentiation. ( 29425279 )
2018
6
Calcium supplementation in osteoporosis: useful or harmful. ( 29440373 )
2018
7
Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis. ( 29425296 )
2018
8
Development of an mHealth Application for Women Newly Diagnosed with Osteoporosis without Preceding Fractures: A Participatory Design Approach. ( 29438343 )
2018
9
TUBB3 E410K syndrome with osteoporosis and cough syncope in a patient previously diagnosed with atypical Moebius syndrome. ( 29289389 )
2018
10
Association Between Vitamin K Epoxide Reductase (VKORC1) -1639G>A Polymorphism and Osteoporosis in Postmenopausal Women. ( 29437025 )
2018
11
Referral patterns to an osteoporosis clinic for dermatology patients undergoing prolonged corticosteroid therapy. ( 29447676 )
2018
12
Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration. ( 29429076 )
2018
13
Gout as a risk factor for osteoporosis: epidemiologic evidence from a population-based longitudinal study involving 108,060 individuals. ( 29383389 )
2018
14
Comparison of three tools for predicting primary osteoporosis in an elderly male population in Beijing: a cross-sectional study. ( 29440880 )
2018
15
Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. ( 29251033 )
2018
16
Autophagy as a target for glucocorticoid-induced osteoporosis therapy. ( 29427075 )
2018
17
Just the FRAX: Management ofA Glucocorticoid-Induced Osteoporosis. ( 29337149 )
2018
18
Does the Association of Comorbidity with 1-Year Mortality After Hip Fracture Differ According to Gender? The Norwegian Epidemiologic Osteoporosis Studies (NOREPOS). ( 29427505 )
2018
19
Psychometric properties and assessment of the Osteoporosis Health Belief Scale among the general Arabic population. ( 29440877 )
2018
20
The increase in bone mineral density by bisphosphonate with active vitamin D analogue is associated with the serum calcium level within the reference interval in postmenopausal osteoporosis. ( 29451049 )
2018
21
Using a sequential explanatory mixed method to evaluate the therapeutic window of opportunity for initiating osteoporosis treatment following fragility fractures. ( 29445831 )
2018
22
Minimally invasive transforaminal lumbar interbody fusion using bone cement-augmented pedicle screws for lumbar spondylolisthesis in patients with osteoporosis. Case series and review of literature. ( 29322970 )
2018
23
Should women be screened for osteoporosis at midlife? ( 29447485 )
2018
24
Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study. ( 29440213 )
2018
25
Effect of Traditional Chinese Medicine Product, QiangGuYin, on Bone Mineral Density and Bone Turnover in Chinese Postmenopausal Osteoporosis. ( 28512501 )
2017
26
Transplantation of HGF modified Dental Pulp Stem Cells Prevents Bone Loss in the Early Phase of Ovariectomy-induced Osteoporosis. ( 28950723 )
2017
27
Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women. ( 28523260 )
2017
28
Comment on 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. ( 28941168 )
2017
29
The osteogenesis-promoting effects of alpha-lipoic acid against glucocorticoid-induced osteoporosis through the NOX4, NF-kappaB, JNK and PI3K/AKT pathways. ( 28611356 )
2017
30
Epidemiology of Bone Fracture in Female Trauma Patients Based on Risks of Osteoporosis Assessed using the Osteoporosis Self-Assessment Tool for Asians Score. ( 29137199 )
2017
31
SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis. ( 28937996 )
2017
32
Targeting osteoblastic casein kinase-2 interacting protein-1 to enhance Smad-dependent BMP signaling and reverse bone formation reduction in glucocorticoid-induced osteoporosis. ( 28128304 )
2017
33
Renal Osteodystrophy or Kidney-Induced Osteoporosis? ( 28497212 )
2017
34
The LIFTMOR-M (Lifting Intervention For Training Muscle and Osteoporosis Rehabilitation for Men) trial: protocol for a semirandomised controlled trial of supervised targeted exercise to reduce risk of osteoporotic fracture in older men with low bone mass. ( 28611110 )
2017
35
Association between primary biliary cholangitis and osteoporosis: meta-analysis. ( 28948408 )
2017
36
Reduced prealbumin is associated with bone mineral density in women with osteoporosis. ( 27727007 )
2017
37
TNF-I+ Promotes Osteoclastogenesis through JNK Signaling-Dependent Induction of Semaphorin3D Expression in Estrogen-Deficiency Induced Osteoporosis. ( 28059444 )
2017
38
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. ( 28585373 )
2017
39
Comparison of tissue transglutaminase 2 and bone biological markers osteocalcin, osteopontin and sclerostin expression in human osteoporosis and osteoarthritis. ( 27357308 )
2017
40
Novel Homozygous LRP5 Mutations in Mexican Patients with Osteoporosis-Pseudoglioma Syndrome. ( 29131652 )
2017
41
Effect of intervention initiation timing of pulsed electromagnetic field on ovariectomy-induced osteoporosis in rats. ( 28510268 )
2017
42
Alpinumisoflavone protects against glucocorticoid-induced osteoporosis through suppressing the apoptosis of osteoblastic and osteocytic cells. ( 29203387 )
2017
43
Variable Expressivity and Response to Bisphosphonate Therapy in a Family with Osteoporosis Pseudoglioma Syndrome. ( 28891484 )
2017
44
Evaluation of the anti-osteoporotic effect of Ginkgo biloba L. in Wistar rats with glucocorticoid-induced-osteoporosis by bone densitometry using dual-energy x-ray absorptiometry (DEXA) and mechanical testing. ( 29044313 )
2017
45
Osteoporosis in Stickler syndrome. A new family case with bone histology study. ( 28159459 )
2017
46
Denosumab treatment in postmenopausal women with osteoporosis. ( 28938991 )
2017
47
Women's Health: Polycystic Ovarian Syndrome, Menopause, and Osteoporosis. ( 28501236 )
2017
48
The Prevalence and Risk Factors of Osteoporosis among a Saudi Female Diabetic Population. ( 28507624 )
2017
49
Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. ( 28529755 )
2017
50
Bone: Towards a better management of glucocorticoid-induced osteoporosis? ( 28855696 )
2017